A patient with pembrolizumab-induced fatal polymyositis.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.12.019
Abstract: Regulatory approval for the anti-programmed death 1 (PD-1) receptor monoclonal antibody (mAb) pembrolizumab represented a major therapeutic advance for patients with metastatic solid cancers [1]. As anticipated, immune checkpoint blockade of the PD-1/programmed death-ligand 1… read more here.
Keywords: polymyositis patient; fatal polymyositis; patient pembrolizumab; pembrolizumab induced ... See more keywords